CXCR3 and COVID-19: It remains to be seen whether the inhibition of CXCL10 production from epithelial cells could have a therapeutic potential in selected COVID-19 patients at increased risk of severe disease, by limiting the infiltration of CXCR3+ immune cells into lung tissue.